FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221031726> ?p ?o ?g. }

• W4221031726 endingPage "e003416" @default.
• W4221031726 startingPage "e003416" @default.
• W4221031726 abstract "Tumor-associated macrophages (TAMs) secreting IL-10 could be a specific functional cell subset with distinct polarization state and suppressive role in antitumor immune response. Here, we assessed the associations of clinical outcome, therapeutic responses and molecular features with IL-10+TAMs infiltration, and potential impact of IL-10+TAMs on the immune contexture in muscle-invasive bladder cancer (MIBC).In this retrospective study, 128 patients and 391 patients with MIBC from Zhongshan hospital (ZS cohort) and The Cancer Genome Atlas cohort were included respectively. Immunohistochemistry was performed to quantify various immune cell infiltration in the ZS cohort. Single cell RNA sequencing and flow cytometry were performed to examine the functional status of IL-10+TAMs and its correlation with other immune cells. Survival analyses and assessment of the adjuvant chemotherapy (ACT) benefit analyses were also performed.High IL-10+TAMs infiltration was associated with inferior prognosis in terms of overall survival and recurrence-free survival, but superior chemotherapeutic response in MIBC. IL-10+TAMs with suppressive features were associated with immunoevasive tumor microenviroment characterized by exhausted CD8+ T cells, immature NK cells and increased immune checkpoint expression. Additionally, high IL-10+TAMs infiltration showed a strong linkage with basal-featured subtype and augmented EGF signaling.Immunosuppresive IL-10+TAMs contributed to an evasive contexture with incapacitated immune effector cells and increased immune checkpoint expression, therefore, predicting unfavorable clinical outcomes despite better ACT responsiveness. IL-10+TAMs might provide guidance for customized selection of EGFR-targeted therapy, FGFR3-targeted therapy as well as immunotherapy. The potential of immunosuppressive IL-10+TAMs as a therapeutic target is worth further exploration." @default.
• W4221031726 created "2022-04-03" @default.
• W4221031726 creator A5003840849 @default.
• W4221031726 creator A5018149676 @default.
• W4221031726 creator A5024278894 @default.
• W4221031726 creator A5032831981 @default.
• W4221031726 creator A5034840502 @default.
• W4221031726 creator A5046719955 @default.
• W4221031726 creator A5078437135 @default.
• W4221031726 creator A5083553088 @default.
• W4221031726 creator A5087860596 @default.
• W4221031726 date "2022-03-01" @default.
• W4221031726 modified "2023-10-16" @default.
• W4221031726 title "Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer" @default.
• W4221031726 cites W1486665165 @default.
• W4221031726 cites W1889406201 @default.
• W4221031726 cites W1923917571 @default.
• W4221031726 cites W1980808101 @default.
• W4221031726 cites W1981291019 @default.
• W4221031726 cites W1985987855 @default.
• W4221031726 cites W2001717792 @default.
• W4221031726 cites W2025381786 @default.
• W4221031726 cites W2035297454 @default.
• W4221031726 cites W2096616470 @default.
• W4221031726 cites W2106684817 @default.
• W4221031726 cites W2113082145 @default.
• W4221031726 cites W2116331814 @default.
• W4221031726 cites W2117232564 @default.
• W4221031726 cites W2135715642 @default.
• W4221031726 cites W2141487097 @default.
• W4221031726 cites W2142530756 @default.
• W4221031726 cites W2210453860 @default.
• W4221031726 cites W2214176334 @default.
• W4221031726 cites W2323024458 @default.
• W4221031726 cites W2406415524 @default.
• W4221031726 cites W2467564067 @default.
• W4221031726 cites W2509266256 @default.
• W4221031726 cites W2532380331 @default.
• W4221031726 cites W2551911481 @default.
• W4221031726 cites W2564795955 @default.
• W4221031726 cites W2592935721 @default.
• W4221031726 cites W2737082469 @default.
• W4221031726 cites W2763670669 @default.
• W4221031726 cites W2794165001 @default.
• W4221031726 cites W2886085348 @default.
• W4221031726 cites W2894982959 @default.
• W4221031726 cites W2895357007 @default.
• W4221031726 cites W2973129586 @default.
• W4221031726 cites W2975497362 @default.
• W4221031726 cites W3001605540 @default.
• W4221031726 cites W3006405288 @default.
• W4221031726 cites W3007935255 @default.
• W4221031726 cites W3023288864 @default.
• W4221031726 cites W3034913219 @default.
• W4221031726 cites W3035420485 @default.
• W4221031726 cites W3048201207 @default.
• W4221031726 cites W3083613542 @default.
• W4221031726 cites W3168396462 @default.
• W4221031726 cites W3180065911 @default.
• W4221031726 cites W3197817755 @default.
• W4221031726 doi "https://doi.org/10.1136/jitc-2021-003416" @default.
• W4221031726 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35338085" @default.
• W4221031726 hasPublicationYear "2022" @default.
• W4221031726 type Work @default.
• W4221031726 citedByCount "10" @default.
• W4221031726 countsByYear W42210317262022 @default.
• W4221031726 countsByYear W42210317262023 @default.
• W4221031726 crossrefType "journal-article" @default.
• W4221031726 hasAuthorship W4221031726A5003840849 @default.
• W4221031726 hasAuthorship W4221031726A5018149676 @default.
• W4221031726 hasAuthorship W4221031726A5024278894 @default.
• W4221031726 hasAuthorship W4221031726A5032831981 @default.
• W4221031726 hasAuthorship W4221031726A5034840502 @default.
• W4221031726 hasAuthorship W4221031726A5046719955 @default.
• W4221031726 hasAuthorship W4221031726A5078437135 @default.
• W4221031726 hasAuthorship W4221031726A5083553088 @default.
• W4221031726 hasAuthorship W4221031726A5087860596 @default.
• W4221031726 hasBestOaLocation W42210317261 @default.
• W4221031726 hasConcept C121608353 @default.
• W4221031726 hasConcept C126322002 @default.
• W4221031726 hasConcept C143998085 @default.
• W4221031726 hasConcept C167672396 @default.
• W4221031726 hasConcept C203014093 @default.
• W4221031726 hasConcept C2777701055 @default.
• W4221031726 hasConcept C2780352672 @default.
• W4221031726 hasConcept C2780851360 @default.
• W4221031726 hasConcept C502942594 @default.
• W4221031726 hasConcept C71924100 @default.
• W4221031726 hasConcept C8891405 @default.
• W4221031726 hasConceptScore W4221031726C121608353 @default.
• W4221031726 hasConceptScore W4221031726C126322002 @default.
• W4221031726 hasConceptScore W4221031726C143998085 @default.
• W4221031726 hasConceptScore W4221031726C167672396 @default.
• W4221031726 hasConceptScore W4221031726C203014093 @default.
• W4221031726 hasConceptScore W4221031726C2777701055 @default.
• W4221031726 hasConceptScore W4221031726C2780352672 @default.
• W4221031726 hasConceptScore W4221031726C2780851360 @default.
• W4221031726 hasConceptScore W4221031726C502942594 @default.

• next